For the first time, scientists are using patients' urine for accurate treatment of bladder cancer

The Guo Jianming team at Sun Yat-sen Hospital affiliated with Fudan University, the Party Yongjun team at Fudan University's Shanghai School of Medicine, and the Liu Xuefeng team at Georgetown University in the United States collaborated on an innovative study on "noninvasive tumor cell culture and drug sensitivity prediction of bladder cancer through urine". For the first time in the world, the project successfully used urine separation in bladder cancer patients to develop bladder cancer cells that can be steadily amplified for generations, providing the basis for early diagnosis and treatment of bladder cancer and the establishment of a drug-sensitive screening platform for patients with advanced stages. The findings were published recently in Proteins and Cells.
bladder cancer is one of the most common malignant tumors in China's genitourinary system, the recurrence rate of the disease is high, for patients with advanced bladder cancer, such as conventional treatment such as chemotherapy, such as large side effects, poor tolerance, limited efficacy. Even with the latest immunotherapy, the response rate is only 10% to 30%, and there are no effective biomarkers to predict drug efficacy. Therefore, it is urgent to set up a drug-sensitive screening platform to guide the individual treatment of patients, the technical difficulty lies mainly in the culture of tumor progenitocytes and cell acquisition of non-invasive.
Guo Jianming told China Science Daily that the study is the first time that bladder cancer tumor progenitor cells have been acquired through patients' urine invasively, and a large-scale automated drug screening platform has been established to understand the sensitivity of bladder cancer patients to a large number of anti-tumor drugs in a short period of time, and truly achieves an individualized prediction of anti-tumor therapy.
Jiang Shuai, the first author of the study and deputy director of urology at Zhongshan Hospital, said the results would help to understand the possible genetic mutations in each bladder cancer patient from a genetic perspective and to accurately analyze the cause of the disease. At the same time, the technology platform can screen healthy people, with a view to early detection of bladder tumor lesions, to establish bladder cancer prevention, early screening strategy is of great significance.
Jiang Stresses that early identification can help identify mutant carriers who are prone to "rapid progression" of the disease, giving such patients the opportunity to participate in customized clinical trials that provide accurate treatment from the first diagnosis, rather than waiting for the disease to progress under "standard" treatment. (Source: Huang Xin, China Science Journal)
relevant paper information: